Moleculin Biotech Q1 net loss widens as R&D costs rise

Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX

0.00


Overview

  • US clinical-stage pharma reported no Q1 revenue and a wider net loss

  • Company achieved first 45-subject enrollment milestone in pivotal MIRACLE trial for AML

  • Q1 research and development expenses rose, mainly due to expanded MIRACLE clinical trials


Outlook

  • Company expects to unblind MIRACLE trial data for 45 subjects in Q2 2026

  • Moleculin anticipates recruiting 90 MIRACLE trial subjects and unblinding data in Q3 2026

  • Company expects current cash resources to support operations into Q3 2026


Result Drivers

  • MIRACLE TRIAL SPENDING - Co said higher Q1 research and development costs were mainly due to expanded MIRACLE clinical trials in Europe and other research activities

  • TRIAL ENROLLMENT PROGRESS - Co reported achieving first 45-subject enrollment milestone in pivotal MIRACLE trial for AML, with continued enrollment on pace


Company press release: ID:nGNX4Nn8vj


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

-$3.54


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Moleculin Biotech Inc is $22.00, about 900% above its May 14 closing price of $2.20


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.